We describe the case of a patient with a diagnosis of rheumatoid arthritis experiencing a mucocutaneous delayed reaction to golimumab. Anyway, there is no consensus regarding the best management of delayed reactions to biologics. Excluding allergic cross-reactivity or sensitization, we finally tested adalimumab by a graded challenge.